Cargando…

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists

Mostrar otras versiones (1)

Background In January 2021, the Dutch vaccination program against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was started. Clinical studies have shown that systemic reactions occur in up to 50% of vaccine recipients. Therefore, COVID-19 vaccination could affect anticoagulation cont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Visser, Chantal, Biedermann, Joseph S., Nierman, Melchior C., van der Meer, Felix J.M., Gulpen, Anouk J.W., Moors, Yvonne C.F., Cannegieter, Suzanne C., Lijfering, Willem M., Kruip, Marieke J.H.A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899332/ https://www.ncbi.nlm.nih.gov/pubmed/35245945 http://dx.doi.org/10.1055/s-0042-1742628

Ejemplares similares

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2021)

The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists()
por: Visser, Chantal, et al.
Publicado: (2023)

Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
por: Camilleri, Eleonora, et al.
Publicado: (2021)

Switching from vitamin K antagonists to direct oral anticoagulants in non‐valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Influence of rosuvastatin on apolipoproteins and coagulation factor levels: Results from the STAtin Reduce Thrombophilia trial
por: Camilleri, Eleonora, et al.
Publicado: (2023)

Statin use decreases coagulation in users of vitamin K antagonists
por: van Rein, Nienke, et al.
Publicado: (2016)

Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial
por: Orsi, Fernanda A., et al.
Publicado: (2019)

Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study
por: Bakker, Sanne, et al.
Publicado: (2022)

Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands
por: Chen, Qingui, et al.
Publicado: (2023)

Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Zielinski, Gilda Denise, et al.
Publicado: (2019)

Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Zielinski, Gilda D., et al.
Publicado: (2021)

Nutrition and venous thrombosis: An exercise in thinking about survivor bias
por: Lijfering, Willem M., et al.
Publicado: (2018)

Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study
por: Toorop, Myrthe M A, et al.
Publicado: (2021)

Current and future burden of venous thrombosis: Not simply predictable
por: Scheres, Luuk J. J., et al.
Publicado: (2018)

Changes in incidence of hospitalization for cardiovascular diseases during the COVID-19 pandemic in The Netherlands in 2020
por: Kempers, Eva K., et al.
Publicado: (2023)

Predicting the risk of recurrent venous thrombosis: What the future might bring
por: Lijfering, Willem M., et al.
Publicado: (2019)

Development of a clinical prediction model for an international normalised ratio ≥ 4·5 in hospitalised patients using vitamin K antagonists
por: Dreijer, Albert R., et al.
Publicado: (2018)

Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial
por: Schol‐Gelok, Suzanne, et al.
Publicado: (2020)

Coagulation factors II, V, VII, IX, X and XI and mortality – a cohort study
por: Yap, Eng Soo, et al.
Publicado: (2023)

Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial
por: Joosten, Linda P T, et al.
Publicado: (2019)

The daily practice of direct oral anticoagulant use in patients with atrial fibrillation; an observational cohort study
por: Gulpen, Anouk J. W., et al.
Publicado: (2019)

Direct oral anticoagulant use and risk of perioperative bleeding: Evidence of absence or absence of evidence?
por: Lijfering, Willem M., et al.
Publicado: (2018)

Risk prediction of recurrent venous thrombosis; where are we now and what can we add?
por: Timp, Jasmijn F., et al.
Publicado: (2019)

Association of VKORC1 polymorphisms and major bleedings in patients who are treated with vitamin K antagonists
por: van Heteren, D. Max, et al.
Publicado: (2022)

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials
por: Scheres, Luuk J. J., et al.
Publicado: (2018)

Procoagulant factors and future risk of arterial cardiovascular disease in patients with prior venous thrombosis: A cohort study
por: Yap, Eng Soo, et al.
Publicado: (2023)

Estimating incidence of venous thromboembolism in COVID‐19: Methodological considerations
por: Nab, Linda, et al.
Publicado: (2022)

Lipid levels and risk of venous thrombosis: results from the MEGA-study
por: Morelli, Vânia M., et al.
Publicado: (2017)

Making safer preoperative arrangements for patients using vitamin K antagonists
por: van Fessem, Joris, et al.
Publicado: (2017)

Organisation of care for patients using direct oral anticoagulants
por: Gulpen, A. J. W., et al.
Publicado: (2020)

Lupus anticoagulant associates with thrombosis in patients with COVID‐19 admitted to intensive care units: A retrospective cohort study
por: Noordermeer, Tessa, et al.
Publicado: (2022)

The effect of hospital-based antithrombotic stewardship on adherence to anticoagulant guidelines
por: Dreijer, Albert R., et al.
Publicado: (2019)

Clinical outcome of patients with a vitamin K antagonist‐associated bleeding treated with prothrombin complex concentrate
por: Brekelmans, Marjolein P. A., et al.
Publicado: (2017)

The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk
por: Khialani, Deeksha, et al.
Publicado: (2020)

Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists
por: van Rein, Nienke, et al.
Publicado: (2016)

Hypertensive Complications of Pregnancy and Risk of Venous Thromboembolism
por: Scheres, Luuk J.J., et al.
Publicado: (2020)

Glucose levels and diabetes are not associated with the risk of venous thrombosis: results from the MEGA case‐control study
por: Li‐Gao, Ruifang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5vm7j75ub63b2pos0ia3ab1g61